You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January.
The firm attributed lower year-over-year Q3 testing volumes to COVID-19 impacts and a decrease in average reimbursement per test.
Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.
An international group of researchers aim to develop an approach that may be able to diagnose multiple conditions, including pneumonia, tuberculosis, sepsis, with one blood sample.
ProciseDx anticipates bringing rapid, quantitative point-of-care tests to market in 2020 using Lumiphore's metal luminescent reporter technology.
The firm anticipates deploying funds to complete the integration of Biosensia, a developer of multi-analyte assays on a CLIA-waived testing platform.
Kypha develops tests for monitoring immune status and inflammation, while Biosensia's RapiPlex system can run simultaneous multiplex testing up to 24 analytes.
Dendritics develops antibodies against immune system and other cells for the discovery of targets with high diagnostic, prognostic, and therapeutic potential.
The three firms each had 510(k) clearances for multiple products from the FDA last month for marketing.
The firm's CEO said that its assay is applicable in other indications where immunosuppressive therapies are used, such as rheumatoid arthritis.